Active ingredient description

Abarelix is a synthetic decapeptide and antagonist of naturally occurring gonadotropin-releasing hormone (GnRH). Abarelix binds to and blocks the gonadotropin releasing hormone receptor in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. Abarelix is primarily used in oncology to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02B Hormone antagonists and related agents → L02BX Other hormone antagonists and related agents
Discover more medicines within L02BX01

Structural formula

Graphic representation of the active ingredient's molecular structure

Chemical formula: C₇₂H₉₅ClN₁₄O₁₄
Molecular mass: 1,416.09 g/mol

External identifiers

CAS Substance: 183552-38-7
DrugBank Drug: DB00106
KEGG Drug: D02738
PubChem Compound: 16131215
RxNorm Ingredient: 301739
SNOMED-CT Concept: 407128008
Abarelix (substance)
UNII Identifier: W486SJ5824